Search results
Results from the WOW.Com Content Network
Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery. [3] Also used to treat hepatitis C (typically, in combination with ribavarin ), it is no longer recommended due to poor efficacy and adverse side-effects. [ 4 ]
PEGylation (or pegylation) is the process of both covalent and non-covalent attachment or amalgamation of polyethylene glycol (PEG, in pharmacy called macrogol) polymer chains to molecules and macrostructures, such as a drug, therapeutic protein or vesicle, which is then described as PEGylated.
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. [3] For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. [3] [4] For hepatitis B it may be used alone. [5] It is given by injection under the skin. [3] Side effects ...
Pegylated interferon-alpha-2b; Pegylated interferon beta-1a [2] In these formulations, Polyethylene glycol (PEG) is added to make interferon last longer in the body. [3] They are used to treat both hepatitis B, [4] hepatitis C [1] and multiple sclerosis. [2] Pegylated interferon is contraindicated in patients with hyperbilirubinaemia. [citation ...
Pegargiminase (also known as pegylated arginine deiminase) is an investigational drug used in arginine deprivation therapy for treating cancers deficient in argininosuccinate synthetase 1 (ASS1).
Halozyme's business is primarily focused on its proprietary and patented recombinant human hyaluronidase enzyme, rHuPH20. [2] The company's development pipeline is concentrated in clinical stage and pre-clinical stage oncology products, including its proprietary investigational drug, PEGPH20, a pegylated version of rHuPH20, which targets hyaluronan (HA) high tumors.
Pegipanermin (USAN Tooltip United States Adopted Name; developmental code names and proposed brand names DN-TNF, INB-03, LIVNate, Quellor XENP345, XPro1595) is a tumor necrosis factor α (TNFα) inhibitor which is under development for the treatment of Alzheimer's disease, mild cognitive impairment, major depressive disorder, and other indications.
"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial". Journal of Inherited Metabolic Disease. 42 (3): 534– 544. doi: 10.1002/jimd.12080. PMID 30834538. S2CID 73489645